首页 | 本学科首页   官方微博 | 高级检索  
     

雷珠单抗治疗息肉状脉络膜血管病变的疗效观察
引用本文:王达良,罗曼,缪茶英,罗素荣. 雷珠单抗治疗息肉状脉络膜血管病变的疗效观察[J]. 国际眼科杂志, 2016, 16(11): 2079-2081. DOI: 10.3980/j.issn.1672-5123.2016.11.23
作者姓名:王达良  罗曼  缪茶英  罗素荣
作者单位:312000,中国浙江省绍兴市人民医院眼科
基金项目:2013年度深圳市福田区卫生公益性科研项目(No.FTWS201366)
摘    要:目的:比较玻璃体腔内注射雷珠单抗在不同类型的息肉状脉络膜血管病变治疗中的临床疗效。
  方法:选取2013-05/2015-05在绍兴市人民医院治疗的63例63眼息肉状脉络膜血管病变患者作为研究对象,根据息肉数的差异分为单息肉组(38例38眼)和多息肉组(25例25眼),两组患者均接受玻璃体腔内注射雷珠单抗治疗,每月1次,连续注射3mo。注射后随访1a,比较两组患者治疗后最佳矫正视力( best corrected visual acuity, BCVA)和中心视网膜厚度( central retinal thickness,CRT)的变化。
  结果:与多息肉组比较,单息肉组治疗前最大线性直径更大、纤维血管性视网膜色素上皮脱离发生率更低、BCVA更低(P<0.05)。治疗后3、6mo,1a单息肉组BCVA明显低于多息肉组(P<0.05);单息肉组治疗后3、6mo,1a时BCVA较治疗前均显著下降( P<0.05)。单息肉组和多息肉组患者的CRT在治疗后6、12mo有统计学差异(P<0.05);单息肉组治疗后3、6mo,1a时CRT均较治疗前低( P<0.05),多息肉组治疗后3、6 mo的CRT较治疗前低( P<0.05)。结论:玻璃体腔内注射雷珠单抗在多息肉型息肉状脉络膜血管病变中治疗效果更好,息肉数量对于评估预后具有重要意义。

关 键 词:雷珠单抗  息肉状脉络膜血管病变  最佳矫正视力  中心视网膜厚度
收稿时间:2016-06-08
修稿时间:2016-09-28

Effect of intravitreal Ranibizumab treatment in polypoidal choroidal vasculopathy with different types
Da-Liang Wang,Man Luo,Cha-Ying Miao and Su-Rong Luo. Effect of intravitreal Ranibizumab treatment in polypoidal choroidal vasculopathy with different types[J]. International Eye Science, 2016, 16(11): 2079-2081. DOI: 10.3980/j.issn.1672-5123.2016.11.23
Authors:Da-Liang Wang  Man Luo  Cha-Ying Miao  Su-Rong Luo
Affiliation:Department of Ophthalmology, Shaoxing People''s Hospital, Shaoxing 312000, Zhejiang Province, China,Department of Ophthalmology, Shaoxing People''s Hospital, Shaoxing 312000, Zhejiang Province, China,Department of Ophthalmology, Shaoxing People''s Hospital, Shaoxing 312000, Zhejiang Province, China and Department of Ophthalmology, Shaoxing People''s Hospital, Shaoxing 312000, Zhejiang Province, China
Abstract:AIM: To investigate the efficiency of intravitreal ranibizumab therapy(IVR)for polypoidal choroidal vasculopathy(PCV)in single or multiple polyps.

METHODS: A total 63 patients diagnosed with PCV in Shaoxing City People''s Hospital from May 2013 to May 2015 were enrolled and divided into single polyp group and multiple polyps group. All patients received intravitreal ranibizumab 3 monthly and were followed up for 12mo. Observe the changes of best corrected visual acuity(BCVA)and central retinal thickness(CRT)at different time points.

RESULTS: The single polyps group exhibited a better BCVA, shorter greatest linear dimension, and lower prevalence of fibro-vascular pigment epithelial detachment compared with the multiple polyp group before treatment(P<0.05). Significant difference of BCVA were observed at 3, 6 and 12mo between the two groups(P<0.05). BCVA at 3, 6, 12mo was significantly better than that at baseline in single polyps group. The single polyp group exhibited a significantly thinner CRT at 6 and 12mo compared with multiple polyps group(P<0.05). The single polyp group showed improvement in CRT over the followed up period(P<0.05). The CRT in multiple polyps group at 3 and 6mo significantly decreased compared with preoperative(P<0.05).

CONCLUSION: IVR meet better result in PCV patients with multiple polyp and polyp numbers may be valuable to prognosis.

Keywords:ranibizumab   polypoidal choroidal vasculopathy   best corrected visual acuity   central retinal thickness
本文献已被 万方数据 等数据库收录!
点击此处可从《国际眼科杂志》浏览原始摘要信息
点击此处可从《国际眼科杂志》下载全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号